BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.
0113 Data Byte Dashboard Tx Readouts
BioCentury & Infogram

Product Development

Waiting for COVID-19 therapy readouts: Data Byte

Jan 13, 2021 | 10:21 PM GMT

Almost a year has passed since the first clinical trials for COVID-19 started and only about 7% of the trials testing therapies for the disease have read out.

As of Jan. 11, 49% of therapeutics trials listed in public registries still had end dates or expected readouts in the future, according to BioCentury’s COVID-19 Clinical Trials Dashboard.

The remaining 44% of trials had completed but not yet released data. Many in this category recently finished, suggesting their findings could soon be reported, though data from a large portion of them may never be seen.

BioCentury analyzed therapies in the and registries by their molecular class. The analysis included Phase I-IV trials and those without an FDA-defined phase. The chart below plots therapeutic classes being tested in at least five trials; over 30 additional classes with four or fewer trials are not displayed.

Immunosuppressants dwarf the other 54 classes of therapies for sheer number of clinical trials.

Of the over 1,300 trials, 37% are due to complete by the end of 1H21.

Over 300 passed their estimated completion date in the last quarter of 2020 or the first weeks of 2021 without a read out. 

Of the almost 100 trials that have yielded publications or company disclosures of data, 30 are Phase III trials and 25 are Phase II.

How to gain access

Continue reading with a
two-week free trial.